RORashida V. Orlova

Rashida V. Orlova

*This is an algorithmically generated author record based on publicly available information.

Rashida V. Orlova has a total of 597 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Type 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients

    by R. V. Orlova, I. A. Gerk, I. M. Itkin, O. V. Cheverda, I. V. Avramenko, N. P. Belyak, N. V. Zhukova, Р. В. Орлова, И. А. Герк, И. М. Иткин, et al.

    The development of immune checkpoint inhibitors (ICIs) has led to significant changes in the treatment strategies for malignant tumors. Results from numerous randomized trials of this class of drugs, alongside their widespread adoption in clinical practice, have demonstrated superior therapeutic efficacy in patients with both locally advanced and disseminated disease. However, the use of ICIs is associated with a range of adverse effects resulting from the strong induction of the patient’s immune response. Unlike other forms of anticancer drug therapy (such as chemotherapy or targeted therapy), the side effects associated with immune checkpoint therapy (ICT) are unpredictable and manifest across various organs and body systems as signs of immune-mediated tissue inflammation. Currently, there are no known predictive factors for the timing, type, or severity of immune-related adverse events associated with ICT. The use of immune checkpoint therapy (ICT) in cancer patients can lead to various disorders, including those affecting the endocrine system. The most common of these are thyroiditis, hypopituitarism, and adrenal insufficiency. However, the literature indicates that type 1 diabetes is also an immune-related complication of ICT. The progression of insulin deficiency in ICT-associated type 1 diabetes occurs more rapidly than in conventional type 1 diabetes. The incidence of type 1 diabetes associated with the use of immune checkpoint inhibitors (ICIs) in cancer patients ranges from 0.3% to 3.5% (1). Immune-related diabetes (irDM) presents with diabetic ketoacidosis or ketosis, typically developing within two weeks of the onset of clinical symptoms of hyperglycemia, such as dry mouth, polydipsia, and polyuria. These symptoms necessitate urgent diagnosis and timely insulin therapy, as endogenous insulin secretion declines within 2–3 weeks of the initial clinical manifestations of diabetes.Furthermore, it has been shown that the level of positive autoantibodies associated with pancreatic islet activity ranges from 5 to 50 MU, while the level of exocrine pancreatic enzymes is only slightly elevated. In this review, we describe the clinical features of type 1 diabetes associated with ICT and present a case from our clinical practice.

  • Open Access

    Immune-mediated hepatitis. A literature review

    by R. V. Orlova, I. M. Itkin, А. К. Ivanova, K. K. Kutcher, Р. В. Орлова, И. М. Иткин, А. К. Иванова, К. К. Кутчер

    Aim. Immune checkpoint inhibitors (ICIs) have transformed the standards of systemic therapy across a broad range of malignancies; however, the expansion of their indications has inevitably been accompanied by a rise in immunerelated adverse events. The aim of this review is to summarise current understanding of the pathogenesis, clinical presentation, incidence, differential diagnosis and management of immune-mediated hepatitis associated with immune checkpoint inhibitor therapy, comparing the approaches adopted by international and Russian professional societies.Methods. Publications were searched in PubMed/MEDLINE and eLIBRARY, as well as on the official websites of the professional societies ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), RUSSCO (Russian Society of Clinical Oncology) and NCCN (National Comprehensive Cancer Network), and of regulatory agencies (FDA Food and Drug Administration). Current clinical guidelines, official prescribing information, systematic reviews, meta-analyses, randomised trials and real-world data were included. Results. The liver ranks third among the organs affected, after the skin and the gastrointestinal tract. According to the integrated safety databases of regulatory agencies, the incidence of immune-mediated hepatitis was 0.7% for pembrolizumab, 1.8% for nivolumab and atezolizumab, 2.8% for durvalumab, and 7.0 to 15.0% for nivolumab combined with ipilimumab, depending on the dose ratio. PD-1 inhibitors were associated with more frequent transaminase elevations than PD-L1 inhibitors. Management is based on stepwise immunosuppression; mycophenolate mofetil is the second-line agent, whereas infliximab is not used in hepatic involvement.Conclusion. Immune-mediated hepatitis requires differential diagnosis, since a substantial proportion of liver test elevations is due to alternative causes. The extent of immunosuppression should be matched to the clinical severity of the condition rather than to the formal CTCAE grade alone.

  • Open Access

    The first domestic combination of nurulimab + prolgolimab: from clinical development and economic analysis to real-world use in disseminated melanoma

    by N. V. Zhukova, R. V. Orlova, I. A. Gerk, A. E. Jukova, I. M. Itkin, I. V. Avramenko, Н. В. Жукова, Р. В. Орлова, И. А. Герк, А. Е. Жукова, et al.

    Immunotherapy with immune checkpoint inhibitors has dramatically shifted the prognosis for outcomes of melanoma treatment. However, enhancing the efficacy of dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 while reducing immune-mediated toxicity remains a clinically significant challenge. This article presents a systematic review of data on the first homegrown fixed-dose combination of dual immune checkpoint inhibitors: anti-CTLA-4 + anti-PD-1 (Nurulimab) + Prolgolimab (Nurdati, BCD-217). We searched articles in the PubMed/MEDLINE, eLIBRARY.ru, ClinicalTrials.gov , Cochrane Library databases, and specialized oncology congress records, using the following keywords in different combinations: unresectable/metastatic melanoma, immunotherapy, checkpoint inhibitors, nurulimab, prolgolimab, Nurdati. A total of 146 articles and information sources were identified at the first stage. After removing duplicates and materials irrelevant to the review topic, 118 records were selected for screening, of which 54 were included in the qualitative analysis. The final review included articles and records covering the molecular and pharmacological properties of nurulimab and prolgolimab, the results of the BCD-217 clinical development, comparative efficacy and safety data, and a cost-effectiveness analysis. The excluded articles got the following reasons in favour of exclusion: inappropriateness, lack of clinical data, duplicate results, and limited access to the full text. In the randomized phase III OCTAVA study, the combination of nurulimab plus prolgolimab demonstrated significantly superior efficacy over prolgolimab monotherapy in terms of median progression-free survival (PFS) with comparable cumulative incidence rates of grade 3–4 AEs. Nurdati is a homegrown innovative medicine that is based on a low-dose CTLA-4 blockade and standard anti-PD-1 therapy, demonstrating durable disease control in a patient with BRAF-wild-type acral melanoma in the presented clinical case.

  • Open Access

    Robot-assisted retroperitoneal lymph node dissection for stage IIA–IIB testicular germ cell tumor

    by E. M. Mamizhev, Мамижев Э. М., R. V. Orlova, Орлова Р. В., D. I. Rumyantseva, Румянцева Д. И., R. A. Melikov, Меликов Р. А., N. F. Krotov, Кротов Н. Ф., et al.

    Background. For a long time, open retroperitoneal lymph node dissection remained the gold standard for the treatment of testicular germ cell tumors. A minimally invasive approach using endoscopic technologies made it possible to solve a number of problems reducing surgical risks for the patient and the perioperative burden for the operating team. Due to the widespread use of robotic surgery in urology, robot-assisted retroperitoneal lymph node dissection (RA-RPLND) has been gaining popularity since its introduction. However, in Russian practice, there are still no published data regarding the discussed technique. Materials and methods. At the N.N. Petrov National Medical Research Center of Oncology, a total of 70 RA-RPLND were performed between June 2022 and May 2025. The requirements for RA-RPLND were: testicular germ cell tumors IA–IIA; residual tumor of the retroperitoneal space before the start of systemic chemotherapy 4 cm in diameter or visualized retroperitoneal lymph nodes up to 2 cm in patients who did not undergo polychemotherapy; normal levels of serum tumor markers (α-fetoprotein, β-human chorionic gonadotropin, lactate dehydrogenase). The operations were performed using the da Vinci Xi robot-assisted surgical system. All patients were treated according to the early rehabilitation program using the ERAS system (Enhanced Recovery After Surgery). Lymph nodes, testicular germ cell tumors risk factors, intra- and postoperative parameters were evaluated. Functional results were also assessed. Results. Mean number of lymph nodes was 30 ± 12. Mean operative time was 209 ± 62 minutes, median intraoperative blood loss was 100 mL, and mean hospital stay was 9 ± 3 days. No perioperative transfusion was required. There were 16 early and no late complications in the postoperative period. Histological examination revealed the following: necrosis in 25 (35.7 %) patients, fibrosis in 3 (4.3 %) patients, mature teratoma in 4 (5.7 %) patients, and viable tumor in 4 (5.7 %) patients. The median postoperative follow-up was 14.8 months. Antegrade ejaculation was achieved in 32.9 % of patients after RA-RPLND. In one patient, ejaculatory status could not be assessed due to erectile dysfunction. Retrograde ejaculation was observed in 47 (67.1 %) patients. Conclusion. RA-RPLND has significant advantages over traditional approaches, including being less invasive, shorter recovery time, and reduced risk of complications. It is necessary to study the long-term results of RA-RPLND in terms of patient survival and quality of life, as well as to develop new technologies aimed at increasing the efficacy and availability of this method.

  • The role of a specialized hospital in the treatment of testicular germ cell tumors (literature review, case studies)

    by Eldar M. Mamizhev, Eldar E. Topuzov, Rashida V. Orlova, Zarema A. Tambieva, Vadim G. Pishchik, Diana I. Rumyantseva, Pavel M. Gorlin, Alexander K. Nosov

  • Open Access

    Ceralasertib as second- or third-line therapy for advanced or metastatic non-small-cell lung cancer without actionable genomic alterations (LOTOS): a multicenter, single-arm, phase 2 trial

    by Artem R. Dorotenko, Доротенко Артем Романович, Mariia S. Shustova, Шустова Мария Станиславовна, Andrey V. Vlasenko, Власенко Андрей Валерьеви, Alexey S. Kiselev, Киселев Алексей Сергеевич, Maria E. Blokhina, Блохина Мария Евгеньевна, et al.

    Background. Despite improved outcomes with immune checkpoint inhibitors in first- or second-line advanced non-small-cell lung cancer (NSCLC) settings, a significant patient population has emerged that either does not respond to or progresses during anti-PD-(L)1-containing therapy. Following progression on platinum-based chemotherapy and PD-(L)1 inhibitor therapies, treatment options for patients with NSCLC are limited. Aim. To evaluate the clinical efficacy and safety of ceralasertib combined with durvalumab for the treatment of advanced or metastatic NSCLC without actionable genomic alterations. Materials and methods. This multicenter, single-arm, phase II study (NCT05941897; randomized clinical trial No. 88, dated February 21, 2023) conducted in Russia enrolled patients with EGFR and ALK wild-type NSCLC who had progressed on first- or second-line platinum-doublet chemotherapy and anti-PD-(L)1 immunotherapy. Eligible patients received oral ceralasertib 240 mg twice daily for 7 consecutive days followed by durvalumab 1500 mg as an intravenous infusion in continuous 28-day treatment cycles until disease progression, unacceptable toxicity, or death. The primary endpoint was investigator-assessed objective response rate (ORR). Secondary endpoints included disease control rate at 18 weeks (DCR), progression-free survival (PFS), duration of response, overall survival (OS), and safety. Results. Between June 2023 and July 2025, 55 patients were screened, of whom 39 received ceralasertib plus durvalumab. The median follow-up time was approximately 9 months. The confirmed ORR was 10.3% (4/39; 95% confidence interval [CI] 2.9–24.2), and DCR was 53.8% (21/39; 95% CI 37.2–69.9). Median PFS was 6.41 months (95% CI 3.71–8.28) and median OS was 18.04 months (95% CI 8.84–23.23). Adverse events (AEs) were reported in 31 patients (79.5%), with 11 (28.2%) experiencing grade ≥3 events. The most common AEs were nausea (53.8%), vomiting (23.1%), respiratory tract infection (20.5%), anemia (15.4%), asthenia (15.4%), fatigue (15.4%), and diarrhea (12.8%). No treatment-related serious adverse events or deaths occurred. Conclusion. The combination of ceralasertib and durvalumab demonstrated a manageable safety profile with clinical activity (as evidenced by PFS and OS) in second- or third-line treatment of patients with advanced or metastatic NSCLC without actionable genomic alterations. These findings support further investigation of this combination in selected patient populations.

  • Open Access

    Variants of the anatomy of the renal vascular bed in patients with retroperitoneal germ cell tumors

    by Eldar M. Mamizhev, Мамижев Эльдар Мухамедович, R. V. Orlova, Орлова Р. В., D. I. Rumyantseva, Румянцева Д. И., R. A. Melikov, Меликов Р. А., Z. A. Tambiyeva, Тамбиева З. А., et al.

    Background. Renovascular anatomy is characterized by complex morphological variations in relation to the number, origin level, length, diameter and topographic relationships of the vessels. Understanding of individual vascular anatomy during the planning of surgical intervention in the retroperitoneal space allows to decrease technical difficulty and achieve better perioperative results. Aim. To study frequencies of renal vessel variant anatomies that can become intraoperative finds in patients with germ cell tumors of the retroperitoneal location due to incomplete preoperative examination creating technical difficulties during surgical treatment. Materials and methods. At the first stage, comparison of a group of 407 patients with germ cell tumors with a control group (401 patients with other oncological diseases) by the presence of vascular anomalies was performed. The second stage consisted of intragroup analysis of operative time, blood loss volume and complications in patients after retroperitoneal lymph node dissection depending on the identified vascular anomaly. Results. Anomalies of renal arteries were identified in 73.2 % of cases in the germ cell tumor group which significantly differed from the control group value of 24.9 % (р = 0.001). The frequency of renal vein anomalies in germ cell tumors was 69.0 % compared to 12.5 % in the control group (р 0.05). Median operative time in the total group was 217.2 ± 0.7 min. Statistically significant differences in increase of operative time in the presence of additional arteries (р = 0.001) and veins (р = 0.002) were observed. Total mean blood loss volume was 389 ± 51.4 mL. Intraoperative blood loss volume significantly depended on injury of additional arteries (р = 0.003) and veins (р = 0.002). Intraoperative complications associated with injury of the main large vessels were observed in 18.7 % of cases. Clinically significand trend was observed towards decreased intraoperative injury of additional and main vessels (total number of injuries 36 (8.9 %) and 76 (18.7 %), respectively; р = 0.017) and, therefore, decreased risk of surgical complications after accumulation of experience in retroperitoneal lymph node dissection and introduction of computed tomography with 3D reconstruction of renal vessels in 2018. Conclusion. Frequency and diversity of various vessels of the retroperitoneal space in patients with germ cell tumors require careful preoperative preparation of the patients in the form of topographic visualization of the vascular network.

  • Open Access

    2nd Saint Petersburg International Consensus on the Diagnosis and Treatment of Breast Cancer «White Nights 2025»

    by Владимир Федорович Семиглазов, Петр Владимирович Криворотько, Татьяна Юрьевна Семиглазова, Елена Владимировна Артамонова, Светлана Геннадьевна Багрова, Елена Михайловна Бит-Сава, Алла Александровна Божок, Лариса Владимировна Болотина, Любовь Юрьевна Владимирова, Вера Андреевна Горбунова, et al.

    В данной публикации представлены результаты II Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2025», который продолжает традицию углубленного обсуждения актуальных и спорных вопросов, возникающих в клинической практике. Под председательством члена-корреспондента РАН, профессора Владимира Федоровича Семиглазова в консенсусе приняли участие ведущие эксперты в области диагностики, хирургии, лучевой терапии и системного лечения рака молочной железы. Эксперты обсудили и проголосовали по 60 ключевым вопросам, касающимся как ранних стадий заболевания, так и метастатического рака молочной железы. Результаты консенсуса обеспечат необходимую основу для дальнейшего совершенствования клинической практики и разработки рекомендаций, направленных на улучшение лечения и качества жизни пациентов с данным заболеванием. Проведение III Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2026» запланировано на 4 июля 2026 г.

  • Open Access

    Stereotactic Radiotherapy in Combination with the Immunoconjugate Trastuzumab Emtansine in Patients with HER2-Positive Oligometastatic Breast Cancer: Final Results of the Efficacy and Safety Study

    by Татьяна Ивановна Севостьянова, Татьяна Юрьевна Семиглазова, Сергей Николаевич Новиков, Жанна Викторовна Брянцева, Ирина Александровна Акулова, Шейда Раджабали Кызы Абдуллаева, Ольга Игоревна Понасенко, Мария Сергеевна Кобышева, Юлдуз Зайнутдиновна Татарханова, Кирилл Алексеевич Низовцев, et al.

    Введение. Концепция олигометастатической болезни (ОМБ) ознаменовала смену парадигмы в понимании характера метастатического процесса. В современной научной повестке важное место занимает изучение эффективности комбинации системных методов лечения с методами локального воздействия. Подлежит дальнейшему изучению применение через 24 ч после окончания стереотаксической лучевой терапии (СТЛТ) на олигометастазы (ОМТС) анти-HER2-терапии трастузумабом эмтанзином (T-DM1). Цель. Повышение эффективности лечения больных HER2-позитивным олигометастатическим раком молочной железы (HER2 + омРМЖ) за счет сочетанного воздействия СТЛТ и терапии T-DM1. Материалы и методы. В исследование включено 175 пациентов с HER2 + мРМЖ, проходивших лечение в НМИЦ онкологии им. Н.Н. Петрова (2019–2025). Пациенты, получавшие T-DM1, стратифицированы по характеру метастатического процесса и наличию/срокам СТЛТ с распределением в четыре группы. Выборки сопоставимы (p >0,05) и репрезентативны. Первичная конечная точка – частота объективного ответа (ЧОО); вторичные конечные точки — выживаемость без прогрессирования (ВБП), частота нежелательных явлений (НЯ). Результаты. Наибольшая ЧОО (52,4 %) зарегистрирована в группе № 1. Увеличение интервала между локальным воздействием и началом терапии до ≥ 30 сут снижало ЧОО до 15,4 %. В группах без СТЛТ (3 и 4) ЧОО составила 14,2 и 12,1 % соответственно. При сокращении временного интервала между вмешательствами до 24 ч отмечено значимое улучшение показателей ВБП: шестимесячная ВБП составила 100 % против 81,3 % в группе с интервалом ≥30 сут, а годичная — 100 против 55 % (ОР 0,20; 95 % ДИ 0,09–0,51; р < 0,001). Предикторы более высокой ВБП: проведение СТЛТ (ОР 0,14; 95 % ДИ 0,05–0,36; p < 0,001) и начало терапии T-DM1 через 24 ч после СТЛТ (ОР 0,33; 95 % ДИ 0,13–0,85; p = 0,022). Выводы. Высокая частота контроля заболевания, достигшая 90,5 %, в сочетании со 100 % ВБП как через 6, так и через 12 мес., а также приемлемый профиль токсичности указывают на перспективность предложенной стратегии комбинированной терапии HER2 + омРМЖ. Для окончательной оценки отдаленных результатов и подтверждения безопасности комбинированного подхода требуется продолжительное наблюдение за когортой пациентов.

  • Open Access

    Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+/HER2-Negative Metastatic Breast Cancer

    by Марк Игоревич Глузман, Рашида Вахидовна Орлова, Эльдар Эскендерович Топузов, Елена Александровна Чистякова, Инна Владимировна Авраменко

    Актуальность. Оптимальный режим первой линии гормонотерапии (ГТ) при HR+/HER2 − метастатическом раке молочной железы (мРМЖ) остаётся предметом дискуссии. Исследование SONIA показало отсутствие значимого выигрыша от назначения ингибиторов CDK4/6 (иCDK4/6) всем пациенткам в первой линии, однако критерии отбора больных, для которых комбинированная ГТ обязательна, не определены. Тип гормонорезистентности (ГР) является биологически обоснованным кандидатом на роль такого предиктора. Цель. Оценить влияние типа ГР (отсутствие — ГР0, первичная — ГР1, вторичная — ГР2) на выживаемость без прогрессирования (ВБП) и частоту объективного ответа (ЧОО) при проведении первой линии лечения люминального мРМЖ, а также установить предиктивное значение ГР при сравнении ГТ в монорежиме и комбинированной ГТ (иCDK4/6 + ГТ) в условиях реальной клинической практики. Материалы и методы. В ретроспективное исследование включено 90 пациенток с HR+/HER2− мРМЖ: ГР0 (n = 28), ГР1 (n = 21), ГР2 (n = 41). В первой линии 61 пациентка получала комбинированную ГТ, 29 — монотерапию. Анализ ВБП выполнен методом Каплана – Майера и лог-рангового критерия. Сопоставимость групп оценена критериями Манна – Уитни, χ² и точным критерием Фишера. Результаты. Тип ГР являлся значимым прогностическим фактором (p = 0,0017): медиана ВБП — 28 мес. при ГР0, 22 мес. — при ГР2 и 13 мес. — при ГР1. Несмотря на худший исходный профиль, при первичной ГР комбинированная ГТ статистически значимо превосходила монотерапию по медиане ВБП (16 мес. vs 9 мес.; p = 0,028); ЧОО при моноГТ составила 0 %, при комбоГТ — 16,7 %. При вторичной ГР наблюдался клинически значимый, но статистически недостоверный выигрыш (23 мес. vs 16,5 мес.; p = 0,47). При ГР0 различий не выявлено (32 мес. vs 28 мес.; p = 0,99). Выводы. Первичная ГР является предиктором значимого преимущества комбинированной ГТ и обосновывает обязательное назначение иCDK4/6 в данной когорте. При ГР0 монотерапия ингибиторами ароматазы обеспечивает высокую ВБП, сопоставимую с комбинированной ГТ. Несопоставимость групп по ряду прогностических факторов означает, что наблюдаемый эффект комбинированной ГТ, вероятно, недооценён, а интерпретация результатов должна учитывать ретроспективный характер и наблюдательный дизайн исследования.